Podcasts about pharmaceuticals

Safety alert issued for serious reactions to certain seizure drugs; Drug approved to treat a rare form of tumor; T-cell malignancies reported with cell immunotherapies; organ transplant rejection treatment recalled; CPAP machine associated with reports of burns and fires.

Today's guest fits into one of Raise the Line's favorite categories of people: physician entrepreneur. We've talked before on the podcast about the overlapping qualities of drive, curiosity, and desire for impact that both share, and that last trait is the core interest of Dr. Navin Goyal. A great example is OFFOR Health, a mobile healthcare company he co-founded that expedites care for children in the US who face long waits for procedures. “If you're a four-year-old with dental disease and you're on Medicaid, you have an average nine-to-twelve month wait to get into an operating room.  We can enable that procedure within one month,” says Goyal. His experience with OFFOR led to the formation of LOUD Capital, which allows Goyal and his partners to seek out other business opportunities that have a social impact. Since launching in 2015, LOUD has partnered with over seventy portfolio companies in healthcare and beyond. But despite his success, Goyal has embraced the concept of being an underdog, hence the title of the book about his journey, Physician Underdog, and his weekly newsletter Underdog for Good. Check out this episode with host Shiv Gaglani to find out why he likes the term, what qualities a potential investment needs to have to get him excited and what he sees as a key upside to having physicians working in a variety of industries. Mentioned in this episode:https://www.loud.vc/Underdog for Good NewsletterPhysician Underdog BookBeyond Physician 

One silver lining of the COVID-19 pandemic is a jump in enrollments in public health degree programs and that's welcome news to Dr. Jan Carney, director of the Master of Public Health program at the University of Vermont's Larner College of Medicine, who believes the field needs a massive injection of personnel. “We need probably an 80% increase in people working in state and local health departments to have the essentials of public health.” As Vermont's former Commissioner of Health, Carney knows the challenges public health officials face and brings those insights to Larner's online-only MPH program, which covers the broad domains of the field from epidemiology to biostatistics to environmental health and also exposes students to the particular health challenges in rural communities. The program also prepares students for perhaps the biggest challenge facing the field: communication of health information in an era of misinformation.  To that end, Carney is urging more ascertainment of how different groups of people prefer to receive information and is suggesting a major change in approach. “Maybe we can start to think of public health communication more as a conversation than a one-way information flow.” Join host Michael Carrese for insights from a national force in public health into how education is evolving to prepare public health practitioners for their vital work in challenging times for the profession.Mentioned in this episode: https://www.uvm.edu/publichealth/

Could the medical system as we know it be fundamentally flawed? That's the question our guest, Dr. Jack Wolfson a board-certified cardiologist, compels us to grapple with. From his father's battle with a Parkinson's like illness, to his departure from the largest traditional cardiology group in Arizona, to creating Natural Heart Doctor, his story is an eye-opening exploration of a health approach that prioritizes treating the cause rather than the symptom.

In this episode, Lisa is joined by Seamus Bruner, author and Director of Research at the Government Accountability Institute, they discusses his new book "Controligarchs: Exposing the Billionaire Class, Their Secret Deals, and the Globalist Plot to Dominate Your Life". He shares insights on the influence of billionaires like George Soros, Bill Gates, and Klaus Schwab on society, particularly during the COVID pandemic. Bruner also discusses the consolidation of industries, the role of social media platforms, and the potential impact of central bank digital currencies. Despite the challenges, he expresses optimism that people are becoming more aware of these issues. New episodes debut every Monday & Thursday.See omnystudio.com/listener for privacy information.

In this episode, Lisa is joined by Seamus Bruner, author and Director of Research at the Government Accountability Institute, they discusses his new book "Controligarchs: Exposing the Billionaire Class, Their Secret Deals, and the Globalist Plot to Dominate Your Life". He shares insights on the influence of billionaires like George Soros, Bill Gates, and Klaus Schwab on society, particularly during the COVID pandemic. Bruner also discusses the consolidation of industries, the role of social media platforms, and the potential impact of central bank digital currencies. Despite the challenges, he expresses optimism that people are becoming more aware of these issues. New episodes debut every Monday & Thursday.Follow Clay & Buck on YouTube: https://www.youtube.com/c/clayandbuckSee omnystudio.com/listener for privacy information.

BF & CM Sale products here: code merry2023 Suggest new guests/topics for the podcast ⁠⁠⁠⁠⁠here⁠⁠⁠⁠⁠ Andrew Huberman Podcast on Water⁠ 1. Chlorine study:  https://www.ncbi.nlm.nih.gov/pmc/articles/PMC1518976/ 2. VOCs in our water:  https://mytapscore.com/en-ca/blogs/tips-for-taps/what-are-vocs-and-are-they-in-your-drinking-water https://drinking-water.extension.org/drinking-water-contaminant-volatile-organic-compounds-vocs/#Potential_health_effects_of_volatile_organic_compounds_in_drinking_water 3. Heavy metals: People that consume high levels of heavy metals risk acute and chronic toxicity, liver, kidney, and intestinal damage, anemia, and cancer  https://www.epa.gov/privatewells/potential-well-water-contaminants-and-their-impacts#:~:text=Heavy%20metals%20can%20contaminate%20private,damage%2C%20anemia%2C%20and%20cancer. https://pubmed.ncbi.nlm.nih.gov/28643849/ https://www.breastcancer.org/risk/risk-factors/exposure-to-chemicals-in-water https://dceg.cancer.gov/research/what-we-study/drinking-water-contaminants 4. Parasites: https://pubmed.ncbi.nlm.nih.gov/32417583/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5877040/#:~:text=Cysts%20of%20Giardia%20and%20oocysts,Giardia%20%5B23%2C24%5D. https://academic.oup.com/cid/article/60/8/e36/2462908 https://www.cdc.gov/healthywater/drinking/contamination/germs.html 5. Fluoride studies:  Harvard study on fluoride & bone cancer https://pubmed.ncbi.nlm.nih.gov/16596294/ JAMA study of fluoride in pregnancy & lower IQ scores in kids https://jamanetwork.com/journals/jamapediatrics/fullarticle/2748634 Study on the impact of fluoride on thyroid hormones https://www.researchgate.net/publication/323016912_Impact_of_Drinking_Water_Fluoride_on_Human_Thyroid_Hormones_A_Case-_Control_Study Fluoride linked with brain cancer: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9866357/ 6. Pharmaceuticals in tap water Study on the endocrine disruptors in water & their effects on the reproductive system https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7139484/ https://pubs.acs.org/doi/10.1021/acs.est.8b05592 https://ehp.niehs.nih.gov/doi/10.1289/ehp.1206244 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789304/ https://home.drinkflowater.com/blogs/posts/what-pharmaceuticals-are-found-in-tap-water 7. Personal care products https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8170769/ https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5459316/ 8. Microplastics https://www.mdpi.com/1660-4601/19/9/5283 https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449537/ 9. PFAs aka "Forever Chemicals" https://www.nature.com/articles/s41545-023-00236-y https://www.ewg.org/research/national-pfas-testing Other: EWG - https://www.ewg.org/tapwater/ Project farm: https://www.youtube.com/watch?v=ja0ioX6GSz0 Watch more about tap water: https://youtu.be/ddHUNK3CBBs Checking your water: https://watercheck.com/collections/symptom-checker & https://mytapscore.com/products/advanced-city-water-test Connect with Alex: - Only a couple spots left to work with me! Accepting new clients worldwide - ⁠⁠⁠⁠⁠work with me here⁠⁠⁠⁠⁠ - ⁠⁠Bye Bye Cramps Online Course⁠⁠ - ⁠⁠⁠⁠DUTCH test⁠⁠⁠⁠ - ⁠⁠⁠⁠GI Map test⁠⁠⁠⁠ - ⁠⁠⁠⁠Free resources⁠⁠⁠⁠ - IG: ⁠⁠⁠⁠@nutritionmoderation⁠⁠⁠⁠ - TikTok: ⁠⁠⁠⁠@nutritionmoderation⁠⁠⁠⁠ - ⁠⁠⁠⁠nutritionmoderation.com⁠⁠⁠

This content has been developed for healthcare professionals only. Patients who seek health information should consult with their physician or relevant patient advocacy groups.For the full presentation, slides, and complete CME/MOC/AAPA information, and to apply for credit, please visit us at PeerView.com/JTS865. CME/MOC/AAPA credit will be available until November 13, 2024.Revolutionizing Solid Tumor Treatment, Unleashing the Potential of Antibody–Drug Conjugates: How to Make the Most of the Latest Clinical Evidence to Enhance Patient Care In support of improving patient care, PVI, PeerView Institute for Medical Education, is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.SupportThis activity is supported by independent educational grants from AstraZeneca, Daiichi Sankyo, Inc., and Gilead Sciences, Inc.Disclosure PolicyAll relevant conflicts of interest have been mitigated prior to the commencement of the activity.Faculty/Planner DisclosuresChair/PlannerPaolo Tarantino, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Daiichi Sankyo, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Gilead Sciences, Inc.; and Lilly.Grant/Research Support from AstraZeneca.Speaker for AstraZeneca; Daiichi Sankyo, Inc.; and F. Hoffmann-La Roche Ltd/Genentech, Inc.Faculty/PlannerErika Hamilton, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for Arcus Biosciences, Inc.; Arvinas, Inc.; AstraZeneca; Daiichi Sankyo, Inc.; Deciphera Pharmaceuticals, lnc.; Ellipses Pharma; F. Hoffmann-La Roche Ltd/Genentech, Inc.; Greenwich LifeSciences, Inc.; iTeos Therapeutics; Janssen Pharmaceuticals, Inc.; Lilly; Loxo Oncology; Mersana Therapeutics; Novartis Pharmaceuticals Corporation; Orum Therapeutics; Pfizer; Relay Therapeutics; Seagen Inc.; and Verascity Science (all paid to institution).Grant/Research Support from AbbVie Inc.; Accutar Biotechnology Inc; Acerta Pharma; ADC Therapeutics SA; Akeso Biophanna Co., Ltd.; Amgen Inc.; Aravive; Artios Pharma; Arvinas, Inc.; AstraZeneca; AtlasMedx, Inc.; BeiGene, lnc.; Black Diamond Therapeutics, Inc.; Bliss Biopharmaceutical (Hangzhou) Co., Ltd.; Boehringer lngelheim Pharmaceuticals, lnc.; Cascadian Therapeutics; Clovis Oncology; Compugen; Cullinan Oncology, Inc.; Curis, Inc.; CytomX Therapeutics, Inc.; Daiichi Sankyo, Inc.; Dana-Farber Cancer Institute; Dantari; Deciphera Pharmaceuticals, Inc.; Duality Biologics; eFFECTOR Therapeutics, Inc.; Ellipses Pharma; Elucida Oncology, Inc.; EMD Serano, Inc.; F. Hoffmann-La Roche Ltd/Genentech, Inc.; FUJIFILM Pharmaceuticals U.S.A., Inc.; G1 Therapeutics, Inc.; H3 Biomedicine Inc.; Harpoon Therapeutics; HUTCHMED (China) Limited; lmmunoGen, Inc.; lmmunomedics, Inc.; lncyte; Infinity Pharmaceuticals, Inc.; lnvestisBio; Jacobio Pharmaceuticals Group Co., Ltd.; K-Group Beta, lnc.; Karyopharm; Lilly; Loxo Oncology; Lycera; MabSpace Biosciences Co., Ltd.; MacroGenics, Inc.; Medlmmune, LLC; Mersana Therapeutics; Merus; Millennium Pharmaceuticals, Inc.; Molecular Templates, Inc.; Novartis Pharmaceuticals Corporation; Nucana; Olema Oncology; OncoMed Pharmaceuticals, Inc.; Onconova Therapeutics; Oncothyreon; ORIC Pharmaceuticals, Inc.; Orinove lnc.; Pfizer; PharmaMar; Pieris Pharmaceuticals, Inc.; Pionyr lmmunotherapeutics; Plexxikon; Radius Health, lnc.; Regeneron Pharmaceuticals Inc.; Relay Therapeutics; Repertoire Immune Medicines; Rgenix Inc.; Seagen lnc.; Sermonix Pharmaceuticals; Shattuck Labs Inc.; Stemcentrx, Inc.; Sutro Biopharma, lnc.; Syndax; Syros Pharmaceuticals, Inc.; Taiho Oncology, Inc.; Taplmmune lnc; TESARO, Inc.; Tolmar Pharmaceuticals, Inc.; Torque Therapeutics, Inc.; Treadwell Therapeutics; Verastem, Inc.; Vincerx Pharma; zenithepigenetics; and Zymeworks (all paid to institution).Faculty/PlannerYelena Y. Janjigian*, MD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AbbVie, Inc.; AmerisourceBergen; Arcus Biosciences; AskGene Pharma, Inc.; Astellas Pharma Inc.; AstraZeneca; Basilea Pharmaceutica Ltd.; Bayer Corporation; Bristol Myers Squibb; Daiichi Sankyo Inc.; GlaxoSmithKline; Guardant Health; Imugene Limited; Inspirna, Inc.; Lilly; Merck and Co., Inc.; Merck Serono; Mersana Therapeutics Inc.; Pfizer; Rgenix Inc.; Seagen Inc.; Silverback Therapeutics (ARS Pharmaceuticals) and Zymeworks Inc.Grant/Research Support from Arcus Biosciences; AstraZeneca; Bayer HealthCare Pharmaceuticals, Inc.; Bristol Myers Squibb; Cycle for Survival; Fred's Team; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Inspirna, Inc.; Lilly; Merck and Co., Inc.; National Cancer Institute; Transcenta Holding; and U.S. Department of Defense.Stock Shareholder in Inspirna, Inc.Faculty/PlannerAntonio Passaro, MD, PhD, has a financial interest/relationship or affiliation in the form of:Consultant and/or Advisor for AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; GSK; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Sharp and Dohme; Mundipharma International; Novartis AG; Pfizer; and Takeda Pharmaceutical Company Limited.Grant/Research Support from ArriVent Biopharma; AstraZeneca; Boehringer Ingelheim International GmbH; Bristol Myers Squibb; Daiichi Sankyo, Inc.; Genentech, Inc./F. Hoffmann-La Roche Ltd.; Janssen Global Services, LLC.; Lilly; Merck Serono; Merck Sharp and Dohme; Mirati Therapeutics, Inc.; Pfizer; and RMC Pharmaceutical Solutions Inc.Planning Committee and Reviewer DisclosuresPlanners, independent reviewers, and staff of PVI, PeerView Institute for Medical Education, do not have any relevant financial relationships related to this CE activity unless listed below.

Dr. David Clarke shares how he was in the right place at the right time to see possibly the best healing modality for unexplained chronic pain at work. He learned that the brain can generate real symptoms when high levels of stress are not fully recognized. This occurs in many people with strong, healthy minds, affecting one in six adults and one in three primary care patients.How does the brain do this? Research shows changes in the nerve pathways in the brain. These occur in people with stress, trauma, and repressed emotions that often are linked to Adverse Childhood Experiences (ACEs). With the correct treatment approach, the nerve pathways in the brain can return to normal and the pain will subside.Dr. David Clarke is the President of the Psychophysiologic Disorders Association. His organization's mission is to advance the awareness, diagnosis, and treatment of stress-related, brain-generated medical conditions.To learn more go to www.EndChronicPain.orgFind out more about the All In Running Club at www.allinhealthandwellness.com/all-in-running-clubVisit ConfidenceThroughHealth.com to find discounts to some of our favorite products.Follow me via All In Health and Wellness on Facebook or Instagram.Find my books on Amazon: No More Sugar Coating: Finding Your Happiness in a Crowded World and Confidence Through Health: Live the Healthy Lifestyle God DesignedProduction credit: Social Media Cowboys

David Young, President of R&D at Processa Pharmaceuticals, talks about the FDA's Project Optimus draft guidance on optimal dosage regimens for specific patients. Processa is modifying existing cancer-killing molecules to improve efficacy and decrease side effects by taking into account genetic factors and the benefit-risk profile of each patient. This precision medicine approach will inform clinical trial recruitment, dosing regimens and the number of patients who can be effectively helped.   David explains, "There are a couple of things that make us unique. One is that we're taking the active cancer-killing molecules on the market. It's a given drug that's approved by the FDA, and we know it kills cancer. We've taken that molecule and either changed it slightly or administered it with another drug in some way to decrease or change the drug's metabolism and then to distribute more drug to the cancer cell."   "So, we started to learn how they look at the benefit-risk profile, and we started to develop our version of regulatory science, and that's expanded now over the last 30 years. That expansion into regulatory science now encompasses Project Optimus, which the FDA recently has put out draft guidance on in terms of optimal dosage regimens. They as well put out some documentation on the Project Optimus initiative where you go in to determine the optimal regimen for your patient. Not just any regimen, but the optimal regimen for your patients. If you get an optimal regimen for your patients, maybe that has a certain balance of efficacy and safety. You might come up with something different than we used to do five years ago in terms of the dosage regimen." #ProcessaPharmaceuticals #ProjectOptimus #BenefitRiskProfile #Cancer #PrecisionMedicine #ClinicalTrials processapharmaceuticals.com Download the transcript here  

David Young, President of R&D at Processa Pharmaceuticals, talks about the FDA's Project Optimus draft guidance on optimal dosage regimens for specific patients. Processa is modifying existing cancer-killing molecules to improve efficacy and decrease side effects by taking into account genetic factors and the benefit-risk profile of each patient. This precision medicine approach will inform clinical trial recruitment, dosing regimens and the number of patients who can be effectively helped.   David explains, "There are a couple of things that make us unique. One is that we're taking the active cancer-killing molecules on the market. It's a given drug that's approved by the FDA, and we know it kills cancer. We've taken that molecule and either changed it slightly or administered it with another drug in some way to decrease or change the drug's metabolism and then to distribute more drug to the cancer cell."   "So, we started to learn how they look at the benefit-risk profile, and we started to develop our version of regulatory science, and that's expanded now over the last 30 years. That expansion into regulatory science now encompasses Project Optimus, which the FDA recently has put out draft guidance on in terms of optimal dosage regimens. They as well put out some documentation on the Project Optimus initiative where you go in to determine the optimal regimen for your patient. Not just any regimen, but the optimal regimen for your patients. If you get an optimal regimen for your patients, maybe that has a certain balance of efficacy and safety. You might come up with something different than we used to do five years ago in terms of the dosage regimen." #ProcessaPharmaceuticals #ProjectOptimus #BenefitRiskProfile #Cancer #PrecisionMedicine #ClinicalTrials processapharmaceuticals.com Listen to the podcast here  

Raise the Line's in-depth look at the potential use of psychedelic compounds in mental health treatment continues today with a focus on the role they may play in helping people overcome substance use disorders. Our guest is Dr. Jeeshan Chowdhury, whose own mental health journey led him to found Journey Colab, a company combating addiction through psychedelic care while employing a unique stakeholder model that includes indigenous communities in ownership. “We have put 10% of the founding equity of the company into an irrevocable purpose trust so that the land, the traditions and the people that our medicines and our work are inspired from can benefit from it,” explains Chowdhury. He tells host Shiv Gaglani that indigenous traditions also inform how the company approaches psychedelic therapy itself. “When we look at their use, it is always done in the context of an expert healer, often called a shaman, and it's done as part of a very well-honed protocol and in the context of a larger community.” Check out this thoughtful discussion to find out why Chowdhury thinks of the therapeutic use of psychedelics as akin to surgery, and how Journey Colab is working with rehab center partners to integrate psychedelic care through clinical trials with the goal of creating an integrated treatment program.Mentioned in this episode: https://www.journeycolab.com

Today's episode touches on some regular themes we explore on Raise the Line such as equal access to quality healthcare, provider burnout and the impact of AI on medicine, but on this episode, we have the welcome opportunity to take a look at these key issues from the perspective of a doctor-turned-entrepreneur in Brazil. Today, Dr. Bruno Lagoeiro is an executive at Afya, one of the largest medical education groups in Brazil, but he started out as a med student who was interested in solving problems he and his classmates were encountering. After years of experimentation, and guidance from a business mentor, the solution they developed was Whitebook, a mobile app for clinical decision-support that's used in tens of millions of patient encounters every year in Brazil. Join host Shiv Gaglani as he draws out the details of Dr. Lagoeiro's amazing journey to improve healthcare in a huge and diverse country that faces delivery challenges in poor and remote communities and a provider workforce being drained by bureaucracy. Despite these hurdles, Dr. Lagoeiro has an optimistic message to share about the power of providers to change healthcare and the promise of AI to allow them to focus more on the human aspects of medicine. Mentioned in this episode: Afya

Chinese biotech firms are key players on the international pharmaceuticals market. They produce substances needed to make crucial medicines. That means China has an edge when it comes to both raw materials and technologies.

Economic Club Chairman David Rubenstein interviewed the CEO of Bayer AG, Bill Anderson, covering Bayer's innovations in healthcare and agriculture, his plans for revitalizing the company, and the state of the global economy, among other things.

Georges is a stage IV melanoma with metastasis in the brain cancer survivor. He fought the disease for ten years and had ten surgeries. Pharmaceuticals nearly destroyed his body, so he took the natural holistic route to heal himself, and here he is. This July 12th, was his eleventh year, free of cancer. This experience has radically changed his life! And it became his mission and passion to share his story and inspire and help others to do the same. In 2017, Georges shifted careers from being a Chief Technology Officer to a Holistic Transformational Health coach, Functional Nutritionist, Professional Speaker, Reiki Teacher, and best-selling for the book Beating the Odds, about his holistic journey to conquer advanced cancer. "I see my advanced cancer experience as a blessing because surviving it gave me a chance to sing the song I was born to sing... which is Helping People Transform Their Health and Vitality." He is completing his Rapid Transformation Therapist diploma to add value to his clients. ✨Highlights from the show:  [00:02:09] Holistic journey to conquer cancer. [00:07:02] Malignant melanoma and its treatment. [00:11:05] 10-years of surgeries. [00:16:14] Cancer is not hereditary. [00:19:42] Disease starts from emotional clutter. [00:21:44] Digestion and eating habits. [00:26:01] Scars and decision to stop. [00:40:31] Overcoming self-imposed stress. [00:47:37] Overcoming skepticism and doubts. [00:53:50] Rapid healing and transformation.

In July, Karen Bowling became the new chair of the 340B Health Board of Directors. The West Virginia native is the president and CEO of Princeton Community Hospital and executive vice president of government affairs for West Virginia University Health System (WVU Medicine). In this episode, Bowling discusses her clinical and leadership experience, her 340B advocacy and communications work, and her advice for getting hospital and health system leaders engaged on 340B. Connecting 340B to PatientsBowling has spent decades working in health care since starting her career as an emergency department nurse in a small rural hospital in West Virginia's Wyoming County. Now that she is a regional and national 340B leader, she has a keen understanding of how 340B connects to the patient care mission. She explains how to use that knowledge to engage with the C-suite on these issues.Promoting 340B Advocacy EffortsAs a government relations professional, Bowling knows how crucial it is to advocate for 340B with state and federal lawmakers. She describes how to make and maintain connections with policymakers who play a major role in determining 340B's future.Telling the 340B StoryBowling urges hospitals to communicate about how they use 340B to help patients in need, including through opinion pieces, media briefings, and community events. She recently wrote an op-ed for West Virginia's The State Journal on the benefits of 340B and the harm caused by attempts to limit these benefits.Check out all of our episodes on the 340B Insight podcast website. You also can stay updated on all 340B Health news and information by visiting our homepage. If you have any questions you'd like us to cover in this podcast, email us at podcast@340bhealth.org.Resources Federal Court Rules HRSA Is Unlawfully Restricting Patients Who Qualify for 340B Read Our Full Analysis of the Medicare 340B Pay Cut Remedy HRSA Announces Policy Restricting Use of 340B at New Child Sites After Transition Period West Virginia State Journal: A Health Care Policy We Can All Support

In our second episode of Sex, Drugs and Rock & Roll, we got the chance to interview Charlotte Cruz, who is the co-founder of Alice Mushrooms. Coming from a background in Food Studies, and her co-founder who was in Pharmaceuticals, we loved getting to chat with another female founder as to why she started this amazing company, focused on wellness for women...in the bite of a delicious piece of chocolate. Who doesn't love that? We picked her brain about the benefits of functional mushrooms, the rise in popularity of mushrooms in general from using them as medicine, to microdosing to tripping, and also learned about the struggle to legalize Psilocybin in this country. If you want to know more about Alice Mushrooms, head to their website here and to see the work they are doing to help female veterans at The Hope Project check that out here Created and produced by Claire Donald and Tess Bellomo For merch, our patreon link, social media, and tickets, please visit our page for all the RAM details!

In this episode, we sit down with Shelley Peterson, a seasoned real estate investor and co-founder of Kahuna Investments, to discuss her journey in the world of commercial real estate investing. Shelley shares valuable insights into the challenges and opportunities she has encountered, emphasizing the importance of mentorship and taking action. We also delve into her unique approach to syndication and her commitment to giving back to the community. Key Takeaways: Jump In and Take Action: Shelley's advice for aspiring real estate investors is simple yet powerful – don't overanalyze, take action. She encourages investors to dive into their first deal, whether through partnerships or joint ventures, and gain hands-on experience. Learning by doing is the fastest way to understand the intricacies of the real estate market. Importance of Effective Team Building: Shelley highlights the significance of building an effective team within your real estate investment endeavors. She discusses the book "The Five Dysfunctions of a Team" by Patrick Lencioni, which emphasizes trust, vulnerability, and teamwork as essential elements for success in real estate investing. Surrounding yourself with the right people is key. Community Involvement: Beyond financial success, Shelley and her team are passionate about giving back to the community. They actively engage in charitable activities and emphasize the importance of contributing resources and time to support local causes. As a real estate investor, making a positive impact in the community goes hand in hand with financial success. Shelley Peterson | Real Estate Background President of Kahuna Investments Portfolio: 3,000 units valued at over $250 million Based in: Chandler, AZ Say hi to him at:  kahunainvestments.com LinkedIn Best Ever Book: 12 Rules of Life by Jordan Peterson Greatest Lesson: Finding the faith and courage to undergo a personal reinvention.   BV Captial BAM Capital Rentec Direct

Our big interview with Avadel Pharmaceuticals CEO Greg Divis (AVDL), who explains why Lumryz, a narcolepsy drug that could cost over $200,000 annually, could be a billion dollar a year business. Also biometric security provider Clear Secure (YOU) sees big growth, chips for auto sector are a problem, but not for NXP Semiconductor (NXPI) and Softbank Corporation (SFTBY) takes it on the chin with a multi-billion yen WeWork loss, but are mobile trends a bigger problem? Futurum's The Drill Down with Cory Johnson offers a weekly look at the business stories behind stocks on the move.  It's business news for business people. Every episode of  The Drill Down offers a pithy look at the week's most important business stories and takes a good hard look at four public companies in the news. The Drill Down is a production of The Futurum Group, a leading global technology advisory, media and research firm. Futurum's media platform spans across multiple OTT and VOD channels that have surpassed 9 million views and over 421 million digital and social media impressions. Learn more about your ad choices. Visit megaphone.fm/adchoices

Among the key qualities everyone wants in their healthcare providers is a love of learning and desire to serve others. That's why we at Osmosis are confident Dr. Lewis Nasr will be a great physician and why we chose him to be the first guest in a new series of interviews on Raise the Line we're calling “Next Gen Journeys.” The series will highlight fresh perspectives on medical education and the future of healthcare offered by students and recent graduates from around the globe. Starting with Dr. Nasr is a natural choice because of the many contributions he's made to Osmosis over the last several years including service in the Osmosis Medical Education Fellowship program and being a key contributor to our Year of the Zebra initiative. In this engaging conversation with host Hillary Acer, Lewis brings the perspective of medical students trying to learn in very challenging circumstances in which their personal safety and access to basic needs can be at risk. “It's another layer of obstacles that you have to get through. This gives international students a resilience and adaptability that they can bring to clinical practice.” Lewis also discusses his interest in hematology-oncology and reflects on entering the field at a time of remarkable clinical and technical advancements. “It's exciting to see cancer go from what is perceived as a death sentence to something manageable. I really hope to be part of the scientific wave of making cancer history.” We have no doubt that he will be, and neither will you after hearing from this thoughtful, compassionate young physician. Mentioned in this episode: https://www.osmosis.org/worldhttps://www.osmosis.org/zebrahttps://www.mdanderson.org/

Pharmaceuticals in wastewater has been changing the behaviour of fish. Studies have found some fish are even becoming more aggressive and have a lower sex drive from exposure to traces of anti-depressants and ibuprofen. Katrina Blowers is joined by Ian Wright an Associate professor in Environmental Science to explain what's happening in out wastewater.   Headlines: Optus offering free data in compensation for outage Israel agrees to daily 4 hour humanitarian pauses Australia suffers biggest fall in income compared to OECD   More Taylor Swift tickets on sale today   Follow The Briefing:Instagram: @thebriefingpodcast Facebook: TheBriefingNewsAUTwitter: @TheBriefingAU    See omnystudio.com/listener for privacy information.

Today's Raise the Line guest, Dr. Megan Meyer, has a pretty simple message for proponents of  psychedelic-assisted therapy (PAT) who are concerned that demand for therapists will outstrip supply in the coming years: don't overlook the largest group of mental health providers in the nation. “Social workers provide more mental health services than psychologists, psychiatrists and psychiatric nurses combined and we're embedded everywhere. I don't think the psychedelic renaissance can actually achieve its aims without us,” says Meyer, who is an associate professor at the University of Maryland School of Social Work. Meyers adds that social workers also happened to be well-equipped for PAT because they're trained to act as guides in helping clients find their own voice and not impose their own perspectives or biases.  Getting large numbers trained will require collaboration across disciplines, universities and training institutes such as the project she's working on with colleagues at the university's Schools of Pharmacy and Nursing to survey social workers and nurses regarding their current knowledge and training needs related to psychedelics. Join host Michael Carrese for an expansive conversation about the role social workers can play in minimizing the risks and realizing the potential of psychedelics including issues of bias and diversity, community-based models of post-therapy integration and learning from the practices of indigenous societies.Mentioned in this episode: https://www.ssw.umaryland.edu/

Mark Yunger, Head of Information Technology at Servier Pharmaceuticals, joins host Maryfran Johnson for this CIO Leadership Live interview. They discuss digital therapeutics, future-proofing IT, the potential for GenAI, supporting patients with tech and more.

Pharmaceuticals, Potions And Pipelines by UK Column

Brian Strem, President and CEO of Kiora Pharmaceuticals, is developing a small molecule drug to treat orphan retinal diseases. Their drug KIO-301 restores vision in patients with inherited retinal disease. By giving retinal ganglion cells the ability to sense light, signals can be sent to the brain to effectively see using cells that are not normally light-sensitive.  These molecular photoswitches can change shape based on the presence or absence of light and allow a patient to see the direction and movement of light. Brian explains, "It is dependent on the specific mutation. So, we know that there are certain gene mutations that a child will literally be born with immediate signs and symptoms of that disease. Whether that is immediately being blind, so being born blind, versus some of the other ones where you don't tend to get the onset of disease symptoms until the second, or third decade of life when you have difficulty seeing in the dark. Then all of a sudden, that progresses to losing periph